Historical record - last NADAC effective date: 10/19/2017
Product Information
NEUPOGEN 480 MCG/0.8 ML SYR is a brand product labeled by Amgen Inc., priced at $636.0120 per ML under NDC 55513020910. Its NADAC has been published 228 times since Nov 28, 2013.
Strength
480 ug/.8mL
Manufacturer
Amgen Inc.NDC
55513020910
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
10/19/2017
Active Ingredients
FILGRASTIMApproval Type
Biologic (BLA)
FDA Application
BLA103353On Market Since
10/2/2000
Pharmacological Classes
Price Statistics
The NADAC for NEUPOGEN 480 MCG/0.8 ML SYR has been published 228 times since Nov 28, 2013, and over the history we have for it it has risen 6.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $636.0120 per ML |
|---|---|
| All-time high | $636.0120 (Oct 10, 2018) |
| All-time low | $594.0918 (Nov 19, 2014) |
| Median price | $612.0482 |
| Average price | $613.7327 |
| Largest weekly change | +2.9% (Oct 25, 2017) |
| Weeks tracked | 228 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+6.9%
Last surveyed Oct 10, 2018 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Filgrastim market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amgen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Filgrastim market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Leukocyte Growth Factor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEUPOGEN 480 MCG/0.8 ML SYR?
The current National Average Drug Acquisition Cost (NADAC) for NEUPOGEN 480 MCG/0.8 ML SYR, manufactured by Amgen Inc., is $636.0120 per ML (NDC 55513020910), effective Oct 10, 2018.
How has the price of NEUPOGEN 480 MCG/0.8 ML SYR changed over time?
Over the history we have for it, the NADAC for NEUPOGEN 480 MCG/0.8 ML SYR has risen 6.9%. It has been tracked across 228 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for NEUPOGEN 480 MCG/0.8 ML SYR?
Since Nov 28, 2013, the NADAC for NEUPOGEN 480 MCG/0.8 ML SYR has ranged from a low of $594.0918 (Nov 19, 2014) to a high of $636.0120 (Oct 10, 2018), with a median of $612.0482 per ML.
Are there cheaper alternatives to NEUPOGEN 480 MCG/0.8 ML SYR?
No other NADAC-published product currently shares the active ingredient and strength of NEUPOGEN 480 MCG/0.8 ML SYR in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NEUPOGEN 480 MCG/0.8 ML SYR?
NEUPOGEN 480 MCG/0.8 ML SYR (NDC 55513020910) is labeled by Amgen Inc., and CMS classifies it as a brand product.